# Ascentage Pharma

Source: https://onco.cc/companies/ascentage-pharma/  
OnCo record `ascentage-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ascentage is a Chinese biotechnology company built on protein-protein interaction inhibitors: olverembatinib, a third-generation BCR-ABL inhibitor approved in China for T315I-mutant chronic myeloid leukaemia, and the BCL-2 inhibitor lisaftoclax.

## Summary

Ascentage Pharma, based in Suzhou and listed in Hong Kong and, since 2025, on Nasdaq, designs small molecules that block protein-protein interactions in apoptosis and other pathways. Olverembatinib (HQP1351), a BCR-ABL inhibitor active against the T315I mutation, was approved in China in 2021 for resistant chronic myeloid leukaemia and is in global trials with Takeda. Lisaftoclax (APG-2575) is a BCL-2 inhibitor in phase 3 trials in chronic lymphocytic leukaemia and other blood cancers. OnCo records it as a registry sponsor of phase 3 cancer trials.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Ascentage Pharma Group Inc.; 亚盛医药
- Tags: ctgov-sponsor
- HQ: Suzhou
- Type: biotech
- Website: https://www.ascentage.com

## Sources

- Official website: https://www.ascentage.com
- ClinicalTrials.gov: trials led by Ascentage Pharma: https://clinicaltrials.gov/search?lead=Ascentage%20Pharma
- Wikipedia: https://en.wikipedia.org/wiki/Ascentage_Pharma

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Chronic lymphocytic leukaemia](https://onco.cc/cancers/cll/), [Chronic myeloid leukaemia (CML)](https://onco.cc/cancers/cml/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- targets: [BCL-2](https://onco.cc/targets/bcl2/), [BCR::ABL1 (Philadelphia chromosome)](https://onco.cc/targets/bcr-abl/)
- drugs: [Olverembatinib](https://onco.cc/drugs/olverembatinib/)
- companies: [Takeda](https://onco.cc/companies/takeda/)
- trials: [A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia](https://onco.cc/trials/nct06389292/), [A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL](https://onco.cc/trials/nct04496349/), [A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors](https://onco.cc/trials/nct03611868/), [A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)](https://onco.cc/trials/nct06051409/), [A Study of Olverembatinib in SDH-deficient GIST.](https://onco.cc/trials/nct06640361/), [APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or Solid Tumors](https://onco.cc/trials/nct05701306/), [APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors](https://onco.cc/trials/nct04785196/), [Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL](https://onco.cc/trials/nct05147467/), [Study of APG2575 Single Agent and Combination Therapy in Patients With Relapsed/Refractory CLL/SLL](https://onco.cc/trials/nct04494503/), [Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients Relapsed/Refractory AML](https://onco.cc/trials/nct04501120/), [Study of Olverembatinib (HQP1351) in Patients With CML-CP](https://onco.cc/trials/nct06423911/)

---
JSON: https://onco.cc/api/v1/entities/ascentage-pharma.json